Ephraim Tsalik

Ephraim Tsalik, MD, MHS, Ph.D., FIDSA, is the VP and Chief Scientific Officer for Infectious Disease and Acute Care at Danaher, where he leads scientific strategy and innovation focused on infectious disease diagnostics, sepsis, antimicrobial resistance, and acute care. Prior to joining Danaher, Dr. Tsalik led a research program at Duke University focused on the intersection of infectious diseases, genomics, and precision diagnostics that was supported by DARPA, DTRA, VA, U.S. Army, and the NIH. He co-founded Predigen, a company developing host gene expression diagnostics for infectious and inflammatory diseases, which was acquired by Biomeme. He is internationally recognized for his work in host-response biomarkers and the development of novel diagnostic approaches to improve clinical decision-making. Dr. Tsalik remains clinically active at the Durham VA Health Care System and maintains an adjunct appointment with Duke University.